United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - duloxetine delayed-release capsules are indicated for the treatment of: -   major depressive disorder [see clinical studies (14.1)] -   generalized anxiety disorder [see clinical studies (14.2)] -   diabetic peripheral neuropathy [see clinical studies (14.3)] -   chronic musculoskeletal pain [see clinical studies (14.5)] monoamine oxidase inhibitors (maois) the use of maois intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)] . starting duloxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and  warnings and precautions (5.4)] . pregn

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine delayed-release capsules are indicated for the treatment of: -   major depressive disorder [see clinical studies (14.1)] -   generalized anxiety disorder [see clinical studies (14.2)] -   diabetic peripheral neuropathy [see clinical studies (14.3)] -   chronic musculoskeletal pain [see clinical studies (14.5)] monoamine oxidase inhibitors (maois) the use of maois intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)] . starting duloxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and  warnings and precautions (5.4)] . pregn

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - betahistine dihydrochloride - tablets - betahistine dihydrochloride 16 mg - betahistine - betahistine - meniere's syndrom. symptomatic treatment of peripheral vertigo.

Ireland - English - HPRA (Health Products Regulatory Authority)

auden mckenzie (pharma division) ltd - methadone hydrochloride - oral solution - 1 mg/ml - drugs used in opioid dependence

Malta - English - Medicines Authority

abbott healthcare products b.v. - betahistine dihydrochloride 16 mg - tablet

Malta - English - Medicines Authority

abbott healthcare products b.v. - betahistine dihydrochloride 8 mg - tablet

Malta - English - Medicines Authority

abbott healthcare products b.v. - betahistine dihydrochloride 24 mg - tablet

Malta - English - Medicines Authority

martindale pharmaceuticals limited bampton road, harold hill, romford essex, rm3 8ug, united kingdom - methadone hydrochloride - oral solution - methadone hydrochloride 2 mg/ml - other nervous system drugs

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - betahistine dihydrochloride - tablet - betahistine dihydrochloride 8 mg - other nervous system drugs

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - betahistine dihydrochloride - tablet - betahistine dihydrochloride 16 mg - other nervous system drugs